Skip to main content
TheraVet SA logo

TheraVet SA — Investor Relations & Filings

Ticker · ALVET ISIN · BE0974387194 LEI · 984500804EBR3F1EFF71 BR Manufacturing
Open in API
Filings indexed 239 across all filing types
Latest filing 2024-10-29 AGM Information
Country BE Belgium
Listing BR ALVET

About TheraVet SA

https://www.egeiro.com/

TheraVet SA is a veterinary biotechnology company specializing in the development and commercialization of treatments for osteoarticular diseases in companion animals. The company focuses on creating a portfolio of pharmaceutical products and solutions designed to manage bone and joint conditions, such as osteoarthritis. Its primary objective is to provide innovative therapeutic options to improve the mobility and quality of life for pets.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
AGM Information Classification · 99% confidence The document explicitly states it is a "Compte-rendu de l'Assemblée Générale Extraordinaire de TheraVet du 28 octobre 2024" (Minutes/Report of the Extraordinary General Meeting). It details the resolutions passed, including a name change and capital structure adjustments, which are typical outcomes of a General Meeting. Since the document reports the results and decisions made during the meeting, it aligns best with the category for AGM-related materials. Although it is a report of the meeting, the closest specific category provided that covers general meeting outcomes is AGM-R (AGM Information), which covers presentations and materials shared during the AGM. Given the content is the official report/minutes of the EGM, AGM-R is the most appropriate fit among the choices, as DVA (Declaration of Voting Results) is too narrow, focusing only on the results, whereas this document details the entire proceedings and decisions.
2024-10-29 French
CP_TheraVet_AG_FR.pdf
AGM Information Classification · 99% confidence The document explicitly states it is a "Compte-rendu de l'Assemblée Générale Extraordinaire de TheraVet du 28 octobre 2024" (Minutes/Report of the Extraordinary General Meeting). It details the resolutions passed, including a name change and capital structure adjustments, which are typical outcomes of a General Meeting. Since the document reports the results and decisions made during the meeting, it aligns best with the category for AGM-related materials. Although it is a report of the meeting, the closest specific category provided that covers general meeting outcomes is AGM-R (AGM Information), which covers presentations and materials shared during the AGM. Given the content is the official report/minutes of the EGM, AGM-R is the most appropriate fit among the choices, as DVA (Declaration of Voting Results) is too narrow, focusing only on the results, whereas this document details the entire proceedings and decisions.
2024-10-28 French
20241028_TheraVet_DDV.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information relative au Nombre Total de Droits de Vote et d'Actions (Article 15 de la loi du 02 mai 2007)" and explicitly states it is publishing the total number of shares and voting rights following capital increases. It provides detailed tables comparing figures as of August 31, 2024, and September 30, 2024. This type of mandatory disclosure regarding the total number of shares and voting rights, often triggered by capital changes, relates directly to the company's capital structure and shareholder rights. While it touches upon capital changes (CAP), its primary function is a regulatory disclosure about the current voting structure. This specific type of mandatory disclosure regarding the total number of shares and voting rights is best classified under Share Issue/Capital Change (SHA) as it directly reports the resulting capital structure, or potentially Regulatory Filings (RNS) if a more specific code isn't available. However, since the core content is the resulting share count after financing activities, SHA is a strong candidate. Given the options, and the focus on the total number of shares and voting rights, SHA (Share Issue/Capital Change) is the most appropriate fit, as the context is the result of recent capital increases. If the document was purely about a change in a major shareholder's stake, MRQ would apply, but this is about the total issued capital.
2024-10-28 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information relative au Nombre Total de Droits de Vote et d'Actions (Article 15 de la loi du 02 mai 2007)" and explicitly states it is publishing the total number of shares and voting rights following capital increases. It provides detailed tables comparing figures as of August 31, 2024, and September 30, 2024. This type of mandatory disclosure regarding the total number of shares and voting rights, often triggered by capital changes, relates directly to the company's capital structure and shareholder rights. While it touches upon capital changes (CAP), its primary function is a regulatory disclosure about the current voting structure. This specific type of mandatory disclosure regarding the total number of shares and voting rights is best classified under Share Issue/Capital Change (SHA) as it directly reports the resulting capital structure, or potentially Regulatory Filings (RNS) if a more specific code isn't available. However, since the core content is the resulting share count after financing activities, SHA is a strong candidate. Given the options, and the focus on the total number of shares and voting rights, SHA (Share Issue/Capital Change) is the most appropriate fit, as the context is the result of recent capital increases. If the document was purely about a change in a major shareholder's stake, MRQ would apply, but this is about the total issued capital.
2024-10-28 French
TheraVet - AGE 2024 (28 OCT) - Procuration - Personnes Morales_Legal Entities.pdf
Proxy Solicitation & Information Statement Classification · 98% confidence The document is titled "Procuration d'actionnaire (Personnes Morales)" / "Shareholder proxy (Legal Entities)" and contains instructions and a form for shareholders to designate a proxy holder for an upcoming meeting. The agenda items explicitly mention an "assemblée générale extraordinaire" (extraordinary general meeting of shareholders) and include resolutions related to capital increases and statutory changes. This document is a proxy form used to solicit votes for a general meeting, which falls under the category of Proxy Solicitation & Information Statement (PSI). It is not the notice of the meeting itself (which would be a PSI or RNS), nor is it the minutes of the meeting (AGM-R).
2024-10-17 French
TheraVet - AGE 2024 (28 OCT) - Procuration - Personnes Physiques_Natural Persons.pdf
Proxy Solicitation & Information Statement Classification · 98% confidence The document is titled "Procuration d'actionnaire (Personnes Physiques)" / "Shareholder proxy (Natural Persons)" and contains a form for shareholders to designate a proxy holder for an upcoming meeting. The text explicitly mentions the date of the meeting (October 28, 2024) and details the agenda items, which include resolutions regarding capital increases and authorized capital. This document is a proxy form used to solicit votes for a general meeting of shareholders. This aligns directly with the definition of Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to provide information and request votes for meetings. It is not the meeting presentation (AGM-R), the full annual report (10-K), or just a dividend notice (DIV).
2024-10-17 French

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.